FTLF

FitLife BrandsA

Nasdaq / Household & Personal Products

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$14.00

+26.6% vs current

Most likely

Base case

45%

Probability

Target price

$10.50

-5.1% vs current

B-

Bear case

30%

Probability

Target price

$7.50

-32.2% vs current

AI sentiment snapshot

Latest data as of 2026-06-11

AI commentary

Evidence quality is good because the main operating claims are backed by the May 14, 2026 company earnings release attached to the 8-K, but forward visibility is still modest. Recent coverage is thin and mostly secondary, there is no reliable analyst-revision trail in the packet, and the analyst target summary lacks a usable target count. That keeps the setup in cautious monitoring territory despite some improving monthly and channel indicators.

RankAlpha Sentiment Codex - 2026-06-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-14catalystQ1 growth was acquisition-led while margins and EPS compressedMedium impact

First-quarter 2026 revenue rose 59% to $25.3 million, but gross margin fell to 37.6% from 43.1% and net income declined to $1.7 million from $2.0 million as Irwin carried a lower margin profile and acquisition-related amortization and interest expense remained a drag [#SEC-8K-2026-05-14].

2026-06-30eventManagement flagged improving monthly trends, Amazon traction, and a June Kroger launchHigh impact

Management said monthly revenue improved sequentially through Q1, Irwin Amazon sales rose from about $0.5 million in December 2025 to about $0.8 million in March 2026 and about $0.9 million in April, and two MusclePharm SKUs were set to launch in several hundred Kroger stores beginning in June; whether those green shoots outweigh weak consumer demand and prior out-of-stock issues is the near-term operating checkpoint [#SEC-8K-2026-05-14].

2027-03-31catalystDebt paydown and normalization at Irwin remain the main rerating leverHigh impact

The company ended Q1 with $37.6 million on the term loan, $4.2 million on the revolver, cash of $1.2 million, and net debt of about $40.6 million; management also said free cash flow is still being allocated to debt reduction after a $1.5 million term-loan amortization payment and a $1.4 million revolver paydown in the quarter. A cleaner rerating likely needs sustained deleveraging plus better supply-chain execution and product availability at Irwin [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-11 • Updated nightlySource: Internal modelMethodology